Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Siles, MG; Lopez-Beltran, A; Pelechano, P; Vicente, AMG; Sarrio, RG; Pena, EGH; Antolin, AR; Zapatero, A; Arranz, JA; Climent, MA.

Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting

Cancers. 2022; 14(16): Nº de citas: 2 [doi:10.3390/cancers14163968]

Hamilton, E; Cortes, J; Ozyilkan, O; Chen, SC; Petrakova, K; Manikhas, A; Jerusalem, G; Hegg, R; Huober, J; Zhang, W; Chen, YY; Martin, M.

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR +, HER2-metastatic breast cancer

BREAST CANCER RESEARCH AND TREATMENT. 2022; 195(1): 55-64 Nº de citas: 7 [doi:10.1007/s10549-022-06662-9]

Martin, M; Hegg, R; Kim, SB; Schenker, M; Grecea, D; Garcia-Saenz, JA; Papazisis, K; Ouyang, QC; Lacko, A; Oksuzoglu, B; Reeves, J; Okera, M; Testa, L; Shimizu, C; Denduluri, N; Adamchuk, H; Dakhil, S; Wei, R; Forrester, T; Fernandez, MM; Zimmermann, A; Headley, D; Johnston, SRD.

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy A Prespecified Analysis of the monarchE Randomized Clinical Trial

JAMA Oncology. 2022; 8(8): 1190-1194 Nº de citas: 39 [doi:10.1001/jamaoncol.2022.1488]

Gil-Herrero, L; Pollan, M; Martin, M; Lopez-Tarruella, S; Castellanos, M; Casla-Barrio, S.

The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross-sectional study: women in Motion 2.0

SUPPORTIVE CARE IN CANCER. 2022; 30(8): 6745-6754 Nº de citas: 7 [doi:10.1007/s00520-022-06993-9]

Escudero-Vilaplana, V; Romero-Medrano, L; Villanueva-Bueno, C; de Diago, MR; Yanez-Montesdeoca, A; Collado-Borrell, R; Campana-Montes, JJ; Marzal-Alfaro, B; Revuelta-Herrero, JL; Calles, A; Galera, M; Alvarez, R; Herranz, A; Sanjurjo, M; Artes-Rodriguez, A.

Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App

Frontiers in Oncology. 2022; 12: [doi:10.3389/fonc.2022.880430]

Farge, D; Frere, C; Connors, JM; Khorana, AA; Kakkar, A; Ay, C; Munoz, A; Brenner, B; Prata, PH; Brilhante, D; Antic, D; Casais, P; Esposito, MCG; Ikezoe, T; Abutalib, SA; Meillon-Garcia, LA; Bounameaux, H; Pabinger, I; Douketis, J.

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

LANCET ONCOLOGY. 2022; 23(7): 334-347 Nº de citas: 41

Vicente-Valor, J; Escudero-Vilaplana, V; Collado-Borrell, R; Lopez-Lopez, C; Villanueva-Bueno, C; Revuelta-Herrero, JL; Ruiz-Briones, P; Somoza-Fernandez, B; Herranz, A; Sanjurjo, M.

Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2022; 28(5): 1259-1263 Nº de citas: 5 [doi:10.1177/10781552221074621]

Santonja Á; Moya-García AA; Ribelles N; Jiménez-Rodríguez B; Pajares B; Fernández-De Sousa CE; Pérez-Ruiz E; Del Monte-Millán M; Ruiz-Borrego M; de la Haba J; Sánchez-Rovira P; Romero A; González-Neira A; Lluch A; Alba E.

Role of germline variants in the metastasis of breast carcinomas.

Oncotarget. 2022; 13: 843-862 Nº de citas: 1 [doi:10.18632/oncotarget.28250]

Chauhan, J; Aasaithambi, S; Marquez-Rodas, I; Formisano, L; Papa, S; Meyer, N; Forschner, A; Faust, G; Lau, M; Sagkriotis, A.

Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis

Jmir Cancer. 2022; 8(2): Nº de citas: 6 [doi:10.2196/35930]

Garcia-Sanchez, S; Collado-Borrell, R; Gonzalez-Haba, E; Revuelta-Herrero, JL; Escudero-Vilaplana, V; Marzal-Alfaro, MB; Sanchez-Fresneda, MN; Mur-Mur, A; Herranz, A; Martin, M; Sanjurjo, M.

A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application

Frontiers in Oncology. 2022; 12: Nº de citas: 3 [doi:10.3389/fonc.2022.889575]

Jimenez-Fonseca, P; Gallardo, E; Arija, FA; Blanco, JM; Callejo, A; Lavin, DC; Rivas, MC; Mosquera, J; Rodrigo, A; Morillas, RS; Gonzalez, MV; Munoz, A; Carmona-Bayonas, A.

Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence

EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2022; 100: 33-45 Nº de citas: 10 [doi:10.1016/j.ejim.2022.02.020]

Bellmunt, J; Valderrama, BP; Puente, J; Grande, E; Bolos, MV; Lainez, N; Vazquez, S; Maroto, P; Climent, MA; del Muro, XG; Arranz, JA; Duran, I.

Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 174: Nº de citas: 11 [doi:10.1016/j.critrevonc.2022.103683]

Kopetz, S; Grothey, A; Van Cutsem, E; Yaeger, R; Wasan, H; Yoshino, T; Desai, J; Ciardiello, F; Loupakis, F; Hong, YS; Steeghs, N; Guren, TK; Arkenau, HT; Garcia-Alfonso, P; Belani, A; Zhang, X; Tabernero, J.

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

Esmo Open. 2022; 7(3): Nº de citas: 10 [doi:10.1016/j.esmoop.2022.100477]

Pacheco-Barcia, V; Munoz, A; Castro, E; Ballesteros, AI; Marquina, G; Gonzalez-Diaz, I; Colomer, R; Romero-Laorden, N.

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair

Cancers. 2022; 14(12): Nº de citas: 13 [doi:10.3390/cancers14122950]

Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Ciruelos, EM; Munoz, M; Bermejo, B; Margeli, M; Csoszi, T; Anton, A; Turner, N; Casas, MI; Morales, S; Alba, E; Calvo, L; De La Haba-Rodriguez, J; Ramos, M; Murillo, L; Santaballa, A; Alonso-Romero, JL; Sanchez-Rovira, P; Corsaro, M; Huang, X; Thallinger, C; Kahan, Z; Gil-Gil, M.

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

EUROPEAN JOURNAL OF CANCER. 2022; 168: 12-24 Nº de citas: 9 [doi:10.1016/j.ejca.2022.03.006]

Jerusalem, G; Delea, TE; Martin, M; De Laurentiis, M; Nusch, A; Beck, JT; Chan, A; Im, SA; Neven, P; Lonshteyn, A; Chandiwana, D; Lanoue, B; Fasching, PA.

Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR +/- HER2-Advanced Breast Cancer in the MONALEESA-3 Trial

CLINICAL BREAST CANCER. 2022; 22(4): 326-335 Nº de citas: 6 [doi:10.1016/j.clbc.2021.12.008]

Van Cutsem, E; Danielewicz, I; Saunders, MP; Pfeiffer, P; Argiles, G; Borg, C; Glynne-Jones, R; Punt, CJA; Van de Wouw, AJ; Fedyanin, M; Stroyakovskiy, D; Kroening, H; Garcia-Alfonso, P; Wasan, H; Falcone, A; Fougeray, R; Egorov, A; Amellal, N; Moiseyenko, V.

First-line trifluridine/tipiracil plus bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

BRITISH JOURNAL OF CANCER. 2022; 126(11): 1548-1554 Nº de citas: 6 [doi:10.1038/s41416-022-01737-2]

Bossi P; Escobar Y; Pea F.

Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice

FRONTIERS IN PAIN RESEARCH. 2022; 3: 893530-893530 Nº de citas: 7 [doi:10.3389/fpain.2022.893530]